Sign in
WithdrawnNo phase

T2 Biomarkers Predictive Value in Occupational Asthma After Cessation of Exposure.

Key facts

Who runs it
University Hospital, Strasbourg, France
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
Jun 2025
Ended
Jun 2026
Type of study
Interventional
Treatments tested
  • Measure of T2 biomarkers
Record updated
23 June 2026
Why it stopped
Because of the negative results reported in other studies

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Age over 18
  • Diagnosis of occupational asthma by specific inhalation challenge
  • Exposure to sensitizing agent avoided or reduced
  • Able to understand the aims and risks of the research and to give free and informed consent
  • For women of childbearing age: effective contraception in progress
  • Benefiting from social security coverage

Who cannot take part

  • Impossibility of giving the subject informed information (subject in emergency situation, difficulties in understanding the subject)
  • Subject under court protection
  • Subject under guardianship or curatorship
  • Pregnant or breast-feeding patient

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Occupational exposure is known to cause 15% of asthma cases. The main treatment for occupational asthma is to stop exposure if possible. Although, remission of occupational asthma only occurs in only 30 % of patients after cessation of exposure. There is currently no way of predicting which patients will go into remission after cessation of exposure.

Read full original descriptionShow less

In non-occupational asthma, the inflammatory biomarker T2 has allowed the entry into personalized medicine and can predict future exacerbations.

The investigators hypothesize that T2 biomarkers could be predictive markers for remission in occupational asthma after exposure cessation.

The investigators intend to carry out a follow-up study at the University Hospital of Strasbourg to perform the non-specific bronchial hyperresponsiveness test to assess remission in patients diagnosed with occupational asthma and to compare baseline T2 biomarkers in remission and non remission patients.

The group in the trial

  • patients with occupational asthmaOther group

    Treatment: Measure of T2 biomarkers

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
23 June 2026